Saturday 17 October 2026
Export IMRX’s income statement to Excel — free account
Immuneering Corporation
IMRX Healthcare Biotechnology
Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00. In the quarter to June 2026, EPS grew 32.5% and free cash flow fell 74.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.59
0.05
−1.37%
Follow IMRX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 15.74 | 3.74 | 3.70 | 1.00 | 1.10 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 33.99 | 17.36 | 14.29 | 7.68 | 10.08 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 32 | 64 | 73 | 68 | 66 | 53 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 2 | 2 | 0 | — | — | — | ||||
| Gross margin, % | — | — | — | 35.67 | 44.61 | 44.56 | 50.09 | — | — | — | |||||
| EBT | — | — | — | (8) | (17) | (34) | (51) | (53) | (61) | (56) | |||||
| EBT margin, % | — | — | — | (401.59) | (737.18) | (1,627.08) | (15,934.89) | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (8) | (17) | (34) | (51) | (53) | (61) | (56) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 1 | 0 | 0 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.08 | 0.47 | 0.15 | 0.01 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.30) | (3.44) | (2.46) | (1.91) | (1.88) | (2.04) | (1.27) | |||||
| Cash flow | — | — | — | (0.18) | (2.95) | (2.27) | (1.67) | (1.72) | (1.83) | (1.03) | |||||
| Capex | — | — | — | 0.00 | (0.01) | 0.00 | (0.03) | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.18) | (2.96) | (2.27) | (1.70) | (1.74) | (1.84) | (1.03) | |||||
| Book value | — | — | — | (0.26) | (4.54) | 11.46 | 4.16 | 3.19 | 1.38 | 4.96 | |||||
| Shares, m | — | — | — | 26 | 5 | 14 | 26 | 28 | 30 | 44 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | ||||
| P/S | — | — | — | 33.89 | 33.89 | 105.83 | 333.79 | — | — | — | |||||
| P/B | — | — | — | 0.00 | 0.00 | 1.41 | 0.96 | — | — | — | |||||
| EV/Sales | — | — | — | 14.35 | 14.35 | 34.10 | 0.91 | — | — | — | |||||
| EV/FCF | — | — | — | (1.71) | (1.71) | (2.29) | (0.01) | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (15) | (31) | (44) | (49) | (55) | (45) | ||||
| Capex | — | — | — | 0 | 0 | 0 | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (4) | (15) | (31) | (45) | (49) | (55) | (45) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 14 | 35 | 147 | 101 | 81 | 32 | 166 | ||||
| Total debt | — | — | — | 17 | 59 | 5 | 5 | — | — | — | |||||
| Net debt | — | — | — | 3 | (37) | (149) | (106) | (86) | (36) | (173) | |||||
| Shareholders’ equity | — | — | — | (7) | (22) | 156 | 110 | 91 | 41 | 218 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (109.20) | (64.86) | (32.70) | (34.95) | (47.54) | (78.61) | (39.36) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (312.34) | (747.69) | (743.47) | (763.99) | (81.29) | |||||
| ROE | — | — | — | 53.15 | 117.48 | (50.24) | (38.00) | (53.36) | (92.51) | (43.12) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Dec 2022
Charts ten years each
Immuneering Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACIU AC Immune | $249.4M | — (loss-making) | — (loss-making) | +29.66% (above 0%: growing) | n/m | +4.66% (above 0%: growing) | 100.00% | (1,321.50%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $236.5M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| SABS SAB Biotherapeutics, Inc. | $235.7M | — (loss-making) | 19.9× | −90.95% (below 0%: shrinking) | n/m | −59.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IMRX Immuneering Corporation | $235.5M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −74.94% (below 0%: shrinking) | 0.00% | 0.00% | |
| QTTB Q32 Bio Inc. | $231.3M | 2.5× | — (loss-making) | −1,928.18% (below 0%: shrinking) | n/m | +71.13% (above 0%: growing) | 100.00% | 0.00% | Compare |
| FATE Fate Therapeutics, Inc. | $230.7M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $224.9M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $224.9M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $231.0M | — | — | −90.95% | — | +6.81% | 100.00% | 0.00% |
Immuneering Corporation (IMRX) key facts
- Immuneering Corporation (IMRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Immuneering Corporation’s revenue for fiscal 2022 (year ended December 2022) was $317,000.00.
- As of October 16, 2026, IMRX traded at $3.59, a market capitalization of $235.5 million.
- Return on equity was −43.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 4.47 (safe zone) for fiscal 2022.